Canopus BioPharma, Inc. Selected to Present its Drug Candidate for HIV/AIDS Treatment at the Global Summit on AIDS and the Church
Published: Dec 03, 2007
LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTCPK:CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today that its President Len Rothstein presented at the Global Summit on AIDS and the Church, which was held from November 28-30, 2007, in Lake Forest, California, as part of the Treatment Horizons Workshop. Mr. Rothstein’s presentation, given on Thursday, November 29, 2007, addressed Canopus BioPharma’s novel antiviral HIV drug SpirH™, which offers new hope for AIDS patients worldwide.